Together with our data showing that S1PR2 mediated high-level DCA-induced intestinal inflammation, these findings provide a strong basis for pharmaceutical studies to verify the efficacy of S1PR2 antagonists in the treatment of inflammatory diseases, including IBD. The gene discussed is S1PR2; the disease is inflammatory bowel disease.